BIO Share Price | Bio-Rad Laboratories, Inc. Stock Analysis & Recommendation

Q: How big is Bio-Rad Laboratories, Inc.?

Market Cap: As of Jun 18, Bio-Rad Laboratories, Inc. has a market capitalization of 6,337.14 million, classifying it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Bio-Rad Laboratories, Inc. reported net sales of 2,541.11 million and a net profit of -2,164.12 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 6,569.30 million and total assets of 9,364.10 million.

Q: What does Bio-Rad Laboratories, Inc. do?

Overview: Bio-Rad Laboratories, Inc. manufactures and supplies products and systems for life science research, healthcare, and analytical chemistry, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.Financial Snapshot: Net Sales: 585 Million (Quarterly Results - Mar 2025) Net Profit: 64 Million (Quarterly Results - Mar 2025) Market cap: USD 6,337.14 Million (Mid Cap)Key Metrics: P/E: 5.00 Dividend Yield: 0.00% Debt Equity: -0.06 Return on Equity: 17.30% Price to Book: 0.95Contact Details: Address: 1000 ALFRED NOBEL DR, HERCULES CA: 94547-1811 Tel: 1 510 7247000 Website: http://www.bio-rad.com/

Q: Is Bio-Rad Laboratories, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for Bio-Rad Laboratories, Inc. has changed from sideways to mildly bearish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum in the short term. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish across both timeframes. Overall, the indicators suggest a mildly bearish stance.In terms of performance, Bio-Rad has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.79% compared to the S&P 500's 12.22%, and a one-year return of -15.85% versus 17.14% for the benchmark.

Q: Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E ratio of 21.83, while QIAGEN NV stands at 24.20, suggesting that Bio-Rad is trading at a significant discount relative to these competitors.Despite the recent fair valuation, Bio-Rad's stock performance has lagged behind the S&P 500, with a year-to-date return of -5.63% compared to the index's 13.30%. Over the past five years, the company's return has been -44.30%, while the S&P 500 has gained 91.29%. This underperformance reinforces the notion that Bio-Rad is fairly valued, as it struggles to keep pace with broader market trends.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

258.27 k

Shareholding (Dec 2025)

FII

20.10%

Held by 261 FIIs

DII

20.8%

Held by 62 DIIs

Promoter

1.03%

How big is Bio-Rad Laboratories, Inc.?

22-Jun-2025

As of Jun 18, Bio-Rad Laboratories, Inc. has a market capitalization of $6.34 billion, with net sales of $2.54 billion and a net profit of -$2.16 billion over the latest four quarters.

View full answer

What does Bio-Rad Laboratories, Inc. do?

22-Jun-2025

Bio-Rad Laboratories, Inc. manufactures products for life science research, healthcare, and analytical chemistry, with a market cap of approximately $6.34 billion. As of March 2025, it reported net sales of $585 million and a net profit of $64 million.

View full answer

Who are in the management team of Bio-Rad Laboratories, Inc.?

22-Jun-2025

As of March 2022, the management team of Bio-Rad Laboratories, Inc. includes Norman Schwartz (Chairman, President, CEO), Gregory Hinckley (Lead Independent Director), Alice Schwartz, Jeffrey Edwards, Melinda Litherland, and Arnold Pinkston (all Independent Directors).

View full answer

Is Bio-Rad Laboratories, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Bio-Rad Laboratories, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -12.79% compared to the benchmark's 12.22%.

View full answer

Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Bio-Rad Laboratories, Inc. is considered fairly valued with a P/E ratio of 5 and a significant discount compared to peers, but its stock has underperformed the S&P 500 with a year-to-date return of -5.63% and a five-year return of -44.30%.

View full answer

Compare Bio-Rad Laboratories, Inc. with Similar Stocks

QIAGEN NV Bruker Corp.Penumbra, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 2.18% over the last 5 years

The company has declared negative results in Mar'2025 after 3 consecutive positive quarters

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7,124 Million (Small Cap)

P/E

21.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.04

Return on Equity

4.65%

Price to Book

0.96

Revenue and Profits:

Net Sales:

693 Million

(Quarterly Results - Dec 2025)

Net Profit:

720 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.55%

6 Months

-3.86%

1 Year

4.86%

2 Years

-19.2%

3 Years

-42.65%

4 Years

-53.12%

5 Years

-52.43%

Bio-Rad Laboratories, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.29%

EBIT Growth (5y)

-8.37%

EBIT to Interest (avg)

30.77

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.06

Sales to Capital Employed (avg)

0.30

Tax Ratio

21.31%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

4.97%

ROE (avg)

11.09%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.96

EV to EBIT

25.74

EV to EBITDA

14.49

EV to Capital Employed

0.95

EV to Sales

2.64

PEG Ratio

Dividend Yield

ROCE (Latest)

3.71%

ROE (Latest)

4.65%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 108 Schemes (58.03%)

Foreign Institutions

Held by 261 Foreign Institutions (20.1%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 6.16% vs 0.21% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 310.59% vs -207.58% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "693.20",
          "val2": "653.00",
          "chgp": "6.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "114.30",
          "val2": "120.60",
          "chgp": "-5.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.10",
          "val2": "12.30",
          "chgp": "-1.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "848.70",
          "val2": "-497.80",
          "chgp": "270.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "720.00",
          "val2": "-341.90",
          "chgp": "310.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "89.30%",
          "val2": "101.70%",
          "chgp": "-1.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.65% vs -3.92% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 141.20% vs -189.38% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,583.20",
          "val2": "2,566.50",
          "chgp": "0.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "471.50",
          "val2": "503.80",
          "chgp": "-6.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "49.00",
          "val2": "48.90",
          "chgp": "0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "681.50",
          "val2": "-2,698.80",
          "chgp": "125.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "759.90",
          "val2": "-1,844.20",
          "chgp": "141.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "103.00%",
          "val2": "121.20%",
          "chgp": "-1.82%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

693.20

653.00

6.16%

Operating Profit (PBDIT) excl Other Income

114.30

120.60

-5.22%

Interest

12.10

12.30

-1.63%

Exceptional Items

848.70

-497.80

270.49%

Consolidate Net Profit

720.00

-341.90

310.59%

Operating Profit Margin (Excl OI)

89.30%

101.70%

-1.24%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 6.16% vs 0.21% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 310.59% vs -207.58% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

2,583.20

2,566.50

0.65%

Operating Profit (PBDIT) excl Other Income

471.50

503.80

-6.41%

Interest

49.00

48.90

0.20%

Exceptional Items

681.50

-2,698.80

125.25%

Consolidate Net Profit

759.90

-1,844.20

141.20%

Operating Profit Margin (Excl OI)

103.00%

121.20%

-1.82%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.65% vs -3.92% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 141.20% vs -189.38% in Dec 2024

All Annual Results

Company CV

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

Pharmaceuticals & Biotechnology

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Company Coordinates

Company Details

1000 ALFRED NOBEL DR , HERCULES CA : 94547-1811

Tel: 1 510 7247000

http://www.bio-rad.com/

Registrar Details